SynthesisPLoS neglected tropical diseases2025
A review and in silico screening of plant-derived snake venom/toxin inhibitors: ADMET, drug-likeness, and medicinal chemistry profiling.
Synthesis in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Snakebite envenomation remains a pressing global health issue, contributing to high rates of illness and death. It also imposes significant socio-economic burdens on affected communities. Recent conservative estimates suggest that approximately 5.4 million snakebite incidents occur annually, leading to nearly 138,000 fatalities. In Africa alone, as many as 500,000 cases are documented each year. This research seeks to explore phytochemicals reported to exhibit in vitro and in vivo inhibitory effects on snake venom and toxin targets. A systematic review was conducted utilizing six electronic databases for literature searches, including Google Scholar, Web of Science, ScienceDirect, Scopus, Springer, and PubMed. This process identified 213 phytocompounds with inhibitory activity against the specified targets. Computational tools such as SwissADME, pkCSM, ADMETlab, ProTox3, Toxtree, and DataWarrior were employed to assess the absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics, alongside other medicinal chemistry properties of these compounds. The results indicate that several plant-derived molecules effectively inhibit snake venom/toxin targets in vitro and in vivo; however, only a few appear suitable for drug development without further modifications. Among the analyzed compounds, the terpenes labdane lactone and labdane trialdehyde, along with the benzenoid anisic acid, exhibited strong antivenom potential. Notably, anisic acid achieved complete (100%) neutralization of lethality and defibrinogenation induced by the venoms of Naja kaouthia, Daboia russelii, Ophiophagus hannah, and Echis carinatus in both in vivo and in vitro studies. Labdane lactone and labdane trialdehyde, which were isolated from Curcuma antinaia and Curcuma zedoaroides, respectively, demonstrated significant venom-inhibitory activity at a concentration of 22.7 μM and 21.9 μM against Ophiophagus hannah venom. Specifically, labdane lactone exhibited an inhibition rate of 83%, while labdane trialdehyde achieved a 62% inhibition rate against the venom of Ophiophagus hannah along with favorable in silico drug-likeness and ADMET profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.